Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF). Although NOACs substantially reduce intracranial hemorrhage, upper gastrointestinal bleeding (UGIB) remains a frequent and clinically consequential complication. Proton pump inhibitors (PPIs) may reduce UGIB risk; however, concerns regarding long-term safety and pharmacodynamic variability persist. Fexuprazan, a potassium-competitive acid blocker (P-CAB), provides rapid and sustained acid suppression independent of acid activation and CYP2C19 metabolism. No randomized trial has evaluated P-CAB therapy for prevention of UGIB in anticoagulated patients.
Methods FENOX is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) superiority trial. Approximately 1,000 high-risk patients with non-valvular AF initiating NOAC therapy will be randomized 1:1 to receive fexuprazan plus NOAC therapy or NOAC therapy alone. High-risk enrichment includes advanced age, renal impairment, concomitant antiplatelet therapy, prior ulcer disease, or elevated HAS-BLED score. The primary endpoint is clinically relevant upper gastrointestinal bleeding (CR-UGIB) at 12 months, defined according to ISTH criteria. All events will be adjudicated by an independent blinded Clinical Events Committee. Primary analyses will follow the intention-to-treat principle using time-to-event methods.
Results The planned sample size provides 80% power to detect a 50% relative risk reduction in CR-UGIB, assuming a 12-month incidence of 10% in the control group. Interim safety monitoring will be conducted under independent oversight.
Conclusion FENOX is the first randomized trial designed to evaluate a P-CAB-based gastroprotective strategy for prevention of clinically relevant UGIB in high-risk patients receiving NOAC therapy. By integrating high-risk enrichment, pragmatic design, and blinded endpoint adjudication, the study aims to provide rigorous evidence to inform gastroprotective strategies in anticoagulated populations.

Start Date01 Dec 2026

Sponsor / Collaborator

Ewha Womans University Mokdong Hospital

NCT07730138

/ Not yet recruitingPhase 3

A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants With Gastric Ulcer

A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer

Start Date15 Oct 2026

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

NCT07746518

/ Not yet recruitingPhase 3

A Multi-center, Double-blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial and Open-label Extension Study to Evaluate the Efficacy and Safety of DWP14012 for Maintenance Therapy in Patients With Healed Erosive Esophagitis

Start Date01 Sep 2026

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Fexuprazan hydrochloride

100 Translational Medicine associated with Fexuprazan hydrochloride

100 Patents (Medical) associated with Fexuprazan hydrochloride

Literatures (Medical) associated with Fexuprazan hydrochloride

01 May 2026·INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

A randomized, open-label, single-dose study to evaluate the safety and pharmacokinetics of two formulations containing 40 mg of fexuprazan in healthy Korean subjects

Article

Author: Moon, Seol Ju ; Park, Hyung ; Lee, Jin A ; Chae, Jihye ; Kwak, Yong-Geun ; Choi, Yongam ; Hur, Joon ; Kim, Min-Gul

OBJECTIVE:

To evaluate the pharmacokinetics and safety of two 40-mg fexuprazan formulations.

MATERIALS AND METHODS:

This study was an open-label, randomized, single-dose, crossover bioequivalence trial in healthy subjects. 24 subjects were randomized to receive either the test formulation, tablet A (40 mg fexuprazan), or the reference formulation, tablet B (40 mg fexuprazan), with crossover administration. Plasma samples were collected up to 48 hours post-dose and analysed for fexuprazan using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS). Individual pharmacokinetic parameters were derived by noncompartmental analysis. Safety was evaluated throughout the study.

RESULTS:

22 subjects completed the study and were included in the pharmacokinetic analysis. Geometric mean values of area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC_t) was 380.17 and 390.33 ng×h/mL for the test and reference formulations, respectively. Geometric mean values of maximum plasma concentration (C_max) were 29.36 and 31.65 ng/mL for the test and reference formulations, respectively. The 90% confidence intervals (CIs) for the test/reference geometric mean ratios of AUC_t and C_max were 0.9098 - 1.0427 and 0.8665 - 0.9931, respectively. All adverse events were mild, and no serious adverse events occurred.

CONCLUSION:

The novel 40-mg fexuprazan formulation (tablet A) was demonstrated to be bioequivalent to the initially developed formulation (tablet B), with comparable systemic exposure (AUC) and peak concentration (C_max). Both formulations were well tolerated, with no clinically meaningful differences in adverse event profiles.

01 May 2026·HELICOBACTER

Efficacy and Safety of Fexuprazan‐Based Modified High‐Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial

Article

Author: Ahn, Ji Yong ; Kim, Jeong Hwan ; Youn, Young Hoon ; Shim, Ki‐Nam ; Kim, Sang Gyun ; Park, Jung‐Ho ; Kim, Jae J ; Moon, Jeong Seop

ABSTRACT:

Background/Aims:

The eradication efficacy of proton pump inhibitor (PPI)–based standard triple therapy (STT) for Helicobacter pylori infection has declined in Korea, largely because of increasing clarithromycin resistance. High‐dose dual therapy (HDDT) using potent acid suppression represents a promising clarithromycin‐sparing strategy. This study evaluated the efficacy and safety of fexuprazan‐based modified HDDT (m‐HDDT) including bismuth, compared with conventional PPI‐based STT as first‐line eradication therapy.

Methods:

This prospective, multicenter, randomized, open‐label, non‐inferiority trial was conducted at eight tertiary hospitals in Korea. Treatment‐naïve adults with confirmed H. pylori infection were randomized to receive either m‐HDDT (fexuprazan 40 mg twice daily, amoxicillin 1000 mg three times daily, and bismuth subcitrate potassium 300 mg three times daily) or STT (lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, all twice daily) for 14 days. Eradication was assessed by urea breath test 4–8 weeks after therapy. The primary endpoint was the eradication rate in the full analysis set (FAS), with a prespecified non‐inferiority margin of −10%. Safety and compliance were evaluated as secondary outcomes.

Results:

In total, 196 patients were included in the FAS (m‐HDDT, n = 96; STT, n = 100). Helicobacter pylori eradication was achieved in 81.3% of patients in the m‐HDDT group and 79.0% in the STT group, demonstrating non‐inferiority of m‐HDDT (one‐sided Wald test, p = 0.0158). Per‐protocol analysis yielded consistent results ( p = 0.0215). Drug compliance was high in both groups, with mean compliance rates of 97.0% in the m‐HDDT group and 99.0% in the STT group; more than 95% of patients in each group achieved ≥ 80% compliance. The incidence of treatment‐emergent adverse events was comparable between groups (16.7% vs. 14.0%); most events consisted of mild gastrointestinal symptoms. No serious adverse events or treatment discontinuations due to adverse events were observed in either group.

Conclusions:

Fexuprazan‐based m‐HDDT with bismuth was non‐inferior to PPI‐based STT for H. pylori eradication and demonstrated comparable safety and excellent compliance. This clarithromycin‐sparing regimen can be considered an alternative treatment option in regions with high macrolide resistance.

30 Apr 2026·Journal of Neurogastroenterology and Motility

Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Network Meta-analysis

Review

Author: Jeong, Da Mi ; Jung, Da Hyun ; Son, Nak-Hoon ; Gwon, Sohyeon ; Huh, Cheal Wung ; Chang, Jin Won

Background/Aims:

: Potassium-competitive acid blockers (P-CABs) have emerged as promising alternatives to proton pump inhibitors (PPIs) to treat erosive esophagitis (EE). This study aims to compare the efficacy and safety of P-CABs and PPIs in patients with mild to severe EE stratified by treatment phase.

Methods:

: A systematic literature search was conducted using PubMed, MEDLINE, and the Cochrane Central Register of Controlled Trials. Randomized controlled trials comparing the efficacy of P-CABs and PPIs for EE were included. The pooled risk ratios (RRs) and risk differences with 95% confidence intervals (CIs) were calculated. A frequentist network meta-analysis was performed, and treatment ranking was assessed using P-scores.

Results:

: Nineteen studies evaluating 5 P-CABs (vonoprazan, tegoprazan, keverprazan, fexuprazan, and zastaprazan) and 2 PPIs (lansoprazole and esomeprazole) were included. P-CABs demonstrated superior efficacy in healing EE during the initial phase, particularly in patients with severe EE (RR = 1.10; 95% CI, 1.00-1.20) and were also associated with a lower EE recurrence risk during maintenance treatment (RR = 0.59; 95% CI, 0.41-0.85). The efficacy was notably greater in patients with higher EE severity and among cytochrome P450 2C19 extensive metabolizers. The safety profiles of the P-CABs and PPIs were comparable. Vonoprazan consistently ranked the highest for both initial treatment (P-score = 0.68) and maintenance (P-score = 0.94).

Conclusions:

: P-CABs, especially vonoprazan, showed superior efficacy compared to PPIs in both the initial and maintenance treatment of EE. These findings support the use of P-CABs as a potent and reliable first-line option for EE management, particularly in high-risk populations, with acceptable safety outcomes.

News (Medical) associated with Fexuprazan hydrochloride

11 Jun 2025

·pipelinereview.com

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

– The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical’s drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea I June 11, 2025 I Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech’s expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong’s development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. “We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical’s pipeline”, said Jens Frauenfeld, CEO of Salipro Biotech. “This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable.” Seongsoo Park, CEO at Daewoong Pharmaceutical stated, “Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro’s expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts.” About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company’s diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. SOURCE: Daewoong Pharmaceutical Co.

Orphan DrugFast Track

11 Jun 2025

·www.prnewswire.com

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Continue Reading Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. SOURCE Daewoong Pharmaceutical Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan DrugFast Track

07 Apr 2025

·pharma.economictimes.indiatimes.com

Sun Pharma launches its novel licensed brand Fexuclue in India

Mumbai: Indian drug maker, Sun Pharma has launched its its brand Fexuclue tablets version Fexuclue, a novel potassium competitive acid blocker , indicated for the treatment of adults with Erosive Esophagitis of all grades. The drug is marketed by Daewoong Pharmaceutical and Sun Pharma has obtained India rights through a licensing deal under which the Korean-drug maker is entitled to upfront and milestone payments, including royalties. "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management but Fexuclue, is a best-in-class treatment option with the potential to bridge this gap," said Kirti Ganorkar, CEO, India Business, Sun Pharma. In a stock exchange filing, Sun Pharma shared that, “the drug was evaluated in a double-blind, double-dummy, comparative Phase 3 study in adult Indian population and the primary efficacy measure was healing of Erosive Esophagitis which was confirmed endoscopically and was was found to be well tolerated in Indian patients.” “The study met its primary endpoint, where over 95 per cent of the patients achieved Erosive Esophagitis healing by eight weeks,” it added. By Online Bureau ,

Phase 3Clinical ResultLicense out/inDrug Approval

100 Deals associated with Fexuprazan hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D13012	-	-	DB16078

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peptic Ulcer	South Korea	Daewoong Pharmaceutical Co., Ltd.	12 May 2025
Gastroesophageal Reflux	South Korea	Daewoong Pharmaceutical Co., Ltd.	30 Dec 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stomach Ulcer	Phase 3	Indonesia	Daewoong Pharmaceutical Co., Ltd.	15 Oct 2026
Stomach Ulcer	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	15 Oct 2026
Helicobacter pylori infection	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	06 Feb 2024
Esophagitis, Peptic	Phase 3	China	Daewoong Pharmaceutical Co., Ltd.	30 Dec 2021
Gastritis	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	02 Jun 2020
Non-erosive gastro-esophageal reflux disease	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	07 Feb 2019
Non-erosive reflux disease	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	07 Feb 2019
Erosive gastro-esophageal reflux disease	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	13 Dec 2018
Erosive esophagitis	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	13 Dec 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT07326904 (CTgov)	Phase 3	Gastroesophageal Reflux	145	Fexuprazan (Fexuprazan 40 mg)	ilgnigpjdi = pqngtaltpl hnnrvpdveo (xsnvlpbwii, tewueodzpb - tqoqnpvway) View more	-	24 Aug 2026
				Esomeprazole (Esomeprazole 40 mg)	ilgnigpjdi = fvkfpsbtsg hnnrvpdveo (xsnvlpbwii, susktkzywc - fcxtzwbnss) View more
DDW2026	Phase 3	Helicobacter pylori infection First line	461	Fexuprazan 40 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg	gijlxxpydm(rbmntawjfd) = vhhiwaggrg pvhkosghwx (wqcylchutr ) View more	Non-inferior	02 May 2026
				Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg	gijlxxpydm(rbmntawjfd) = ymnxathkgr pvhkosghwx (wqcylchutr ) View more
NCT04784910 (Pubmed \| Gut Liver)	Phase 3	-	-	Fexuprazan 20 mg/day	eswllfdovz(xfmtivvwzz) = mceapzheqx ccisvwzthd (mjddswkrdz ) View more	Positive	15 Sep 2025
				Lansoprazole 15 mg/day	eswllfdovz(xfmtivvwzz) = rgkeiorsgx ccisvwzthd (mjddswkrdz ) View more
NCT04784910 (DDW2025)	Phase 3	Peptic Ulcer	423	Fexuprazan 20 mg/day	nikzzicsfk(fltvbpwtch) = lxkbccbxxv cwqurgfonl (smqkjwehyx ) View more	Non-inferior	03 May 2025
				Lansoprazole 15 mg/day	nikzzicsfk(fltvbpwtch) = wogtjmxawp cwqurgfonl (smqkjwehyx ) View more
NEWS	-	Esophagitis, Peptic	513	非苏拉生	hvbmglxftt(feyfajmchm) = mkrlzkdwyk jsbntlvcqt (kqdhdjxmqm ) View more	Non-inferior	17 Oct 2024
				艾司奥美拉唑	hvbmglxftt(feyfajmchm) = etbwwwizzo jsbntlvcqt (kqdhdjxmqm ) View more
UEGW2024	Not Applicable	-	-	Fexuprazan 40 mg	pcendbwnpg(unhsmqoutl) = wscawwgxew fabqlfcpyv (kbnxsakquh, -2.80 to 9.23) View more	-	13 Oct 2024
				Esomeprazole 40 mg	pcendbwnpg(unhsmqoutl) = fsgopgqaip fabqlfcpyv (kbnxsakquh, -2.80 to 9.23) View more
NCT05813561 (Pubmed) Manual	Phase 3	Erosive esophagitis	332	Fexuprazan 40 mg	xlkpxqtexy(gjgncjockz) = cfcvgrsayj wyrxsgnjdf (dgmhadpqih ) View more	Positive	22 Jan 2024
				Esomeprazole 40 mg	xlkpxqtexy(gjgncjockz) = qqkkwmqkix wyrxsgnjdf (dgmhadpqih ) View more
NCT04341454 (Pubmed \| Gut Liver)	Phase 3	Acute gastritis \| Chronic gastritis	327	Fexuprazan 20 mg q.d.	jwfaibwvvx(sbnxkskxjc) = ynfxmgprji vloyfqymvx (gbbmsmykfr )	-	15 Feb 2023
				Fexuprazan 10 mg b.i.d.	jwfaibwvvx(sbnxkskxjc) = gfbwnnbser vloyfqymvx (gbbmsmykfr )
UEGW2022	Not Applicable	Acute gastritis \| Chronic gastritis	-	Fexuprazan 20 mg q.d.	twvicgsfcy(rgmnivfnom) = pymchinrvl udsxhrvaup (oepozekwar )	-	09 Oct 2022
				Fexuprazan 10 mg b.i.d.	twvicgsfcy(rgmnivfnom) = wtuhyskvqi udsxhrvaup (oepozekwar )
NCT03574415 (Pubmed \| Aliment Pharmacol Ther) Manual	Phase 1	-	80	DWP14012	ltsbkqmvbm(vibjnfauqb) = the mean percentages of time that the intragastric pH was above 4 after multiple doses of 40 mg in the Korean, Caucasian and Japanese subjects were 64.3%, 62.8% and 70.3%, respectively, and the corresponding values for the 80 mg dose were 94.8%, 90.6% and 90.6% respectively. dqlbwjkmfj (jjycenmsot )	Positive	01 Dec 2020
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis